1
|
Ahmed E, Assou S, Foisset F, Bourdais C, Vanheerswynghels M, Petit A, Gamez AS, Gras D, Chanez P, de Vos J, Hammad H, Bourdin A, Lambrecht B. [Modeling T2 high severe asthma using human induced pluripotent stem cells (hiPSC)]. Rev Mal Respir 2024; 41:289-293. [PMID: 38461089 DOI: 10.1016/j.rmr.2024.02.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Accepted: 02/05/2024] [Indexed: 03/11/2024]
Abstract
Severe asthma patients with persistent airflow obstruction are characterized by functional obstruction due to mucus plugs containing mucins, fibrin, and eosinophil derived Charcot- Leyden crystals. The molecular mechanisms underlying this endotype are not clearly understood. Developing new models is crucial to respiratory research insofar as critical differences exist between human and rodent airway epithelium. We (and other teams) have shown that it is possible to reconstitute in vitro a complex and functional airway epithelium displaying all the features described in vivo from human-induced pluripotent stem cells (hiPSC). Our aim is to establish a human in vitro model of severe asthma that will recapitulate airway epithelium remodeling and mucus plugs.
Collapse
Affiliation(s)
- E Ahmed
- Laboratoire d'immunologie muqueuse, centre VIB-UGent pour la recherche sur l'inflammation, université de Gand, 9000 Gand, Belgique; Département de maladies respiratoires, université de Montpellier, CHU de Montpellier, hôpital Arnaud de Villeneuve, Montpellier, France
| | - S Assou
- IRMB, Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - F Foisset
- IRMB, Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - C Bourdais
- IRMB, Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - M Vanheerswynghels
- Laboratoire d'immunologie muqueuse, centre VIB-UGent pour la recherche sur l'inflammation, université de Gand, 9000 Gand, Belgique
| | - A Petit
- Département de maladies respiratoires, université de Montpellier, CHU de Montpellier, hôpital Arnaud de Villeneuve, Montpellier, France
| | - A S Gamez
- Département de maladies respiratoires, université de Montpellier, CHU de Montpellier, hôpital Arnaud de Villeneuve, Montpellier, France
| | - D Gras
- Aix-Marseille université, INSERM, INRAE, C2VN, Marseille, France
| | - P Chanez
- Aix-Marseille université, INSERM, INRAE, C2VN, Marseille, France
| | - J de Vos
- IRMB, Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - H Hammad
- Laboratoire d'immunologie muqueuse, centre VIB-UGent pour la recherche sur l'inflammation, université de Gand, 9000 Gand, Belgique
| | - A Bourdin
- Département de maladies respiratoires, université de Montpellier, CHU de Montpellier, hôpital Arnaud de Villeneuve, Montpellier, France; PhyMedExp, université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France.
| | - B Lambrecht
- Laboratoire d'immunologie muqueuse, centre VIB-UGent pour la recherche sur l'inflammation, université de Gand, 9000 Gand, Belgique; Département de médecine interne et pédiatrie, université de Gand, Gand, Belgique
| |
Collapse
|
2
|
Vachier I, Crestani B, Chanez P, Gonzalez J. [J2R 2022 back in Reims]. Rev Mal Respir 2023; 40:107-108. [PMID: 36801046 DOI: 10.1016/j.rmr.2023.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Accepted: 01/06/2023] [Indexed: 02/18/2023]
Affiliation(s)
- I Vachier
- MED BIO MED, CHU de Montpellier Montpellier, France.
| | - B Crestani
- Centre de compétences des maladies pulmonaires rares, hôpital Bichat, AP-HP, Paris, France
| | - P Chanez
- Pneumologie clinique des bronches, CHU, Marseille, France
| | - J Gonzalez
- Pneumologie hôpital de la Pitié-Salpêtrière, Paris, France
| | | |
Collapse
|
3
|
Valette K, Moreno L, Duez C, Chanez P, Gras D. Influence of culture expansion medium on human bronchial epithelium composition and function. Rev Mal Respir 2022. [DOI: 10.1016/j.rmr.2022.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
4
|
Fouquet H, Giovanelli J, De Nadaï P, Balsamelli J, Berger P, Bourdin A, Chanez P, Fry S, Perez T, Magnan A, Pretolani M, Taillé C, Tsicopoulos A, Chenivesse C. Évaluation de CCL18 comme biomarqueur de l’endotype allergique de l’asthme. Rev Mal Respir 2022. [DOI: 10.1016/j.rmr.2022.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Chebbo M, Assou S, Pantesco V, Duez C, Chanez P, Gras D. Molecular portrait of platelets from patients with severe asthma. Rev Mal Respir 2021. [DOI: 10.1016/j.rmr.2021.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Mankouri F, Sereme Y, Michel M, Piarroux R, Pahus L, Chanez P, Vitte J, Gouitaa M. Immediate Hypersensitivity to Mealworm and Cricket: Beyond Shrimp and House Dust Mite Cross Reactivity. J Investig Allergol Clin Immunol 2021; 32:64-66. [PMID: 33978587 DOI: 10.18176/jiaci.0707] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F Mankouri
- Aix Marseille Univ, APHM, Clinique des bronches allergies et sommeil, Marseille, France
| | - Y Sereme
- Aix-Marseille Univ, IRD, APHM, MEPHI, Marseille, France.,IHU Méditerranée Infection, Marseille, France
| | - M Michel
- Aix-Marseille Univ, IRD, APHM, MEPHI, Marseille, France.,IHU Méditerranée Infection, Marseille, France
| | | | - L Pahus
- Aix Marseille Univ, APHM, Clinique des bronches allergies et sommeil, Marseille, France.,Aix Marseille Univ, CNRS, EFS, ADES - Marseille, France.,Aix Marseille Univ, INSERM U1263, INRA 1260 (C2VN), Marseille, France
| | - P Chanez
- Aix Marseille Univ, APHM, Clinique des bronches allergies et sommeil, Marseille, France.,Aix Marseille Univ, INSERM U1263, INRA 1260 (C2VN), Marseille, France
| | - J Vitte
- Aix-Marseille Univ, IRD, APHM, MEPHI, Marseille, France.,IHU Méditerranée Infection, Marseille, France
| | - M Gouitaa
- Aix Marseille Univ, APHM, Clinique des bronches allergies et sommeil, Marseille, France
| |
Collapse
|
7
|
Capron T, Trigui Y, Gautier C, Puech B, Chanez P, Reynaud-Gaubert M. Respiratory impairment in Niemann-Pick B disease: Two case reports and review for the pulmonologist. Respir Med Res 2019; 76:13-18. [PMID: 31254945 DOI: 10.1016/j.resmer.2019.05.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2019] [Revised: 05/04/2019] [Accepted: 05/06/2019] [Indexed: 11/18/2022]
Abstract
Acid sphingomyelinase deficiency (ASMD), also called Niemann-Pick disease, is a storage disorder with pulmonary involvement but few respiratory symptoms in adults. However, the disease may evolve towards clinically relevant respiratory symptoms with referral to the pulmonologist for management and care. Based on two case reports illustrating respiratory impairment, the aim of this work was to review clinical features, diagnosis, respiratory prognostic and therapeutics for the pulmonologist. Overall, storage disorder should be suspected in the presence of hepatosplenomegaly and interstitial lung disease. Concomitant thrombopenia or hyperlipidemia should also draw attention. Following recent consensus guidelines, diagnosis is based on enzyme assay for ASM activity in blood, with subsequent gene sequencing once the biochemical diagnosis has been confirmed. Disease is slowly progressive and the main causes of death are respiratory and liver failure. Presence of emphysema lesions or worsening of respiratory symptoms should call for the intensification of treatment. Though enzyme replacement therapy is a promising way of development, lung transplantation might be considered for these patients in the absence of contraindication.
Collapse
Affiliation(s)
- T Capron
- Centre de compétences national maladies pulmonaires rares, équipe de transplantation pulmonaire, Aix-Marseille université, CHU Nord, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France.
| | - Y Trigui
- Clinique des bronches, allergies et sommeil, Aix-Marseille université, CHU Nord, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France
| | - C Gautier
- Centre de compétences national maladies pulmonaires rares, équipe de transplantation pulmonaire, Aix-Marseille université, CHU Nord, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France
| | - B Puech
- Service de radiologie, Aix-Marseille université, CHU Nord, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France
| | - P Chanez
- Clinique des bronches, allergies et sommeil, Aix-Marseille université, CHU Nord, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France
| | - M Reynaud-Gaubert
- Centre de compétences national maladies pulmonaires rares, équipe de transplantation pulmonaire, Aix-Marseille université, CHU Nord, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France
| |
Collapse
|
8
|
Rajaoarifetra J, Palot A, Tissier Ducamp D, Tummino C, Gouitaa M, Chanez P. [The obstructive sleep apnoea syndrome is not only bad for the heart!]. Rev Mal Respir 2018; 35:562-566. [PMID: 29773418 DOI: 10.1016/j.rmr.2017.10.666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Accepted: 10/24/2017] [Indexed: 11/29/2022]
Abstract
Obstructive sleep apnoea (OSA) is common in the general population, particularly in the elderly. This syndrome is frequently responsible for severe cardiovascular complications. However, the indications for its treatment in the elderly remain controversial. We report the case of a 79-year-old man with severe, undiagnosed OSA who inhaled his fixed dental bridge during sleep. The inhaled foreign body came to rest in the lumen of the left main stem bronchus. The association of obesity with a body mass index of 30kg/m2, snoring with breathing pauses reported by his partner, nocturia, morning headache and an Epworth score of 11 led to polysomnography which confirmed OSA with an apnoea/hypopnoea index of 53 per hour. This case report emphasises that OSA may constitute a risk fact for foreign body inhalation in elderly subjects due to arousal-induced hyperventilation following the apnoeic event.
Collapse
Affiliation(s)
- J Rajaoarifetra
- Clinique des bronches, allergies et du sommeil, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France; Inserm U1067, CNRS UMR 7333 Aix-Marseille université, 13009 Marseille, France.
| | - A Palot
- Clinique des bronches, allergies et du sommeil, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France; Inserm U1067, CNRS UMR 7333 Aix-Marseille université, 13009 Marseille, France
| | - D Tissier Ducamp
- Clinique des bronches, allergies et du sommeil, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France; Inserm U1067, CNRS UMR 7333 Aix-Marseille université, 13009 Marseille, France
| | - C Tummino
- Clinique des bronches, allergies et du sommeil, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France; Inserm U1067, CNRS UMR 7333 Aix-Marseille université, 13009 Marseille, France
| | - M Gouitaa
- Clinique des bronches, allergies et du sommeil, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France; Inserm U1067, CNRS UMR 7333 Aix-Marseille université, 13009 Marseille, France
| | - P Chanez
- Clinique des bronches, allergies et du sommeil, hôpital Nord, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13015 Marseille, France; Inserm U1067, CNRS UMR 7333 Aix-Marseille université, 13009 Marseille, France
| |
Collapse
|
9
|
Pahus L, Gouitaa M, Sofalvi T, Alagha K, Gras D, Chanez P, Charpin D. Cypress pollen allergy is responsible for two distinct phenotypes of allergic rhinitis different from other pollinosis. Eur Ann Allergy Clin Immunol 2018; 50:28-35. [PMID: 29350019 DOI: 10.23822/eurannaci.1764-1489.34] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Summary Different phenotypes of allergic rhinitis have been identified based on the seasonality of the allergen involved. Within pollinosis, importance has to be paid to the responsible pollen species. Guidelines for clinical management are mostly based on studies performed in patients with grass pollen allergy. Only few data is available on tree pollen allergy and more specifically on cypress pollen allergy. We focused on the clinical and biological features of cypress pollen allergy to determine whether it is associated with a specific phenotype of allergic rhinitis or not. Our results suggest that cypress pollen can be responsible for two distinct phenotypes of rhinitis, both different from other pollinosis. In the most common phenotype, cypress pollen was not responsible for bronchial hyperresponsiveness or systemic inflammation. Close attention has to be paid to the allergen involved in allergic rhinitis. Different phenotypes leading to different pharmacological strategies may apply.
Collapse
Affiliation(s)
- L Pahus
- Aix Marseille Univ, APHM, Espace Éthique Méditerranéen, UMR 7268 ADES / EFS / CNRS, CIC 9502, Clinique des bronches allergies et sommeil Hôpital Nord, 4eme B Chemin des Bourrely 13015 Marseille Phone: +33 04 919 658 64 Fax: +33 04 919 689 02 E-mail:
| | - M Gouitaa
- APHM, Clinique des bronches allergies et sommeil, Marseille, France
| | - T Sofalvi
- APHM, Clinique des bronches allergies et sommeil, Marseille, France
| | - K Alagha
- APHM, Clinique des bronches allergies et sommeil, Marseille, France
| | - D Gras
- UMR INSERM 1067 / CNRS 7333, Marseille, France
| | - P Chanez
- Aix Marseille Univ, APHM, UMR CNRS 7333, CIC 9502, INSERM U1067, Clinique des bronches allergies et sommeil, Marseille, France
| | - D Charpin
- APHM, Pneumology Unit, Hôpital de la Timone, Marseille, France Study conducted in APHM, Clinique des Bronches, allergies et sommeil, Marseille France
| |
Collapse
|
10
|
Cottin V, Gamez A, Chanez P, Israël-Biet D, Bonniaud P, Pestel K, Jouneau S. Facteurs de risque associés à l’arrêt de la pirfénidone chez des patients atteints de fibrose pulmonaire idiopathique (FPI) en vie réelle : données du registre international PASSPORT. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Bourdin A, Gamez A, Ledanois O, Chanez P. Impact du reslizumab sur le recours aux soins chez les patients adultes atteints d’asthme éosinophilique sévère. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Humbert M, Pahus L, Ledanois O, Chanez P. Effet du reslizumab sur la réduction des exacerbations sévères de l’asthme et sur la fonction pulmonaire chez les patients sous traitement de fond par corticostéroïdes oraux. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
13
|
Humbert M, Chanez P, Ledanois O, Bourdin A. Efficacité du reslizumab chez les patients asthmatiques éligibles au traitement par l’omalizumab. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg CM, Girodet PO, Berger P, Kline JN, Chupp G, Susulic VS, Barnathan ES, Baribaud F, Loza MJ, Lam S, Eich A, Ludwig-Sengpiel A, Leigh R, Dransfield M, Calhoun W, Hussaini A, Chanez P. Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients. J Allergy Clin Immunol 2017; 140:710-719. [PMID: 28089872 DOI: 10.1016/j.jaci.2016.11.038] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Revised: 11/06/2016] [Accepted: 11/21/2016] [Indexed: 11/25/2022]
Abstract
BACKGROUND The Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study profiled patients with mild, moderate, and severe asthma and nonatopic healthy control subjects. OBJECTIVE We explored this data set to define type 2 inflammation based on airway mucosal IL-13-driven gene expression and how this related to clinically accessible biomarkers. METHODS IL-13-driven gene expression was evaluated in several human cell lines. We then defined type 2 status in 25 healthy subjects, 28 patients with mild asthma, 29 patients with moderate asthma, and 26 patients with severe asthma based on airway mucosal expression of (1) CCL26 (the most differentially expressed gene), (2) periostin, or (3) a multigene IL-13 in vitro signature (IVS). Clinically accessible biomarkers included fraction of exhaled nitric oxide (Feno) values, blood eosinophil (bEOS) counts, serum CCL26 expression, and serum CCL17 expression. RESULTS Expression of airway mucosal CCL26, periostin, and IL-13-IVS all facilitated segregation of subjects into type 2-high and type 2-low asthmatic groups, but in the ADEPT study population CCL26 expression was optimal. All subjects with high airway mucosal CCL26 expression and moderate-to-severe asthma had Feno values (≥35 ppb) and/or high bEOS counts (≥300 cells/mm3) compared with a minority (36%) of subjects with low airway mucosal CCL26 expression. A combination of Feno values, bEOS counts, and serum CCL17 and CCL26 expression had 100% positive predictive value and 87% negative predictive value for airway mucosal CCL26-high status. Clinical variables did not differ between subjects with type 2-high and type 2-low status. Eosinophilic inflammation was associated with but not limited to airway mucosal type 2 gene expression. CONCLUSION A panel of clinical biomarkers accurately classified type 2 status based on airway mucosal CCL26, periostin, or IL-13-IVS gene expression. Use of Feno values, bEOS counts, and serum marker levels (eg, CCL26 and CCL17) in combination might allow patient selection for novel type 2 therapeutics.
Collapse
Affiliation(s)
| | - Michel Laviolette
- Institut Universitaire de Cardiologie et Pneumologie de Québec (IUCPQ), Quebec City, Quebec, Canada
| | - Dave Singh
- Centre for Respiratory Medicine and Allergy, University of Manchester, and the Medicines Evaluation Unit, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom
| | - J Mark FitzGerald
- Institute for Heart and Lung Health, Lung Centre, Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada
| | - Steven Kelsen
- Department of Thoracic Medicine and Surgery, Temple University School of Medicine, Philadelphia, Pa
| | - Vibeke Backer
- Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark
| | - Celeste M Porsbjerg
- Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark
| | - Pierre-Olivier Girodet
- Université Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, Bordeaux, France
| | - Patrick Berger
- Université Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, Bordeaux, France
| | - Joel N Kline
- Division of Pulmonary, Critical Care, and Occupational Medicine, University of Iowa, Iowa City, Iowa
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Chanez P, Calverley P, Wouters E, Finnigan H, Kay T, Magnussen H. L’éosinophilie sanguine : un marqueur d’exacerbation de BPCO à l’arrêt de la corticothérapie inhalée ? Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Bourdin A, Gamez A, Boissin C, Chanez P. Effet du Reslizumab sur l’utilisation des corticostéroïdes oraux chez les patients asthmatiques sévères avec hyperéosinophilie sanguine : résultats de l’analyse poolée de 2 études de phase III versus placebo. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Chanez P, Pahus L, Alagha K, Sofalvi T, Bourdin A. Amélioration précoce de la fonction respiratoire et du contrôle de l’asthme : un facteur de réponse au reslizumab dans l’asthme sévère ? Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
18
|
Chanez P, Vogelmeier C, Fabbri L, Bell S, Tetzlaff K, Magnussen H, Watz H. Facteurs de risque d’exacerbations dans l’étude Wisdom. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Caillaud D, Chanez P, Escamilla R, Burgel PR, Court-Fortune I, Nesme-Meyer P, Deslee G, Perez T, Paillasseur JL, Pinet C, Jebrak G, Roche N. Asthma-COPD overlap syndrome (ACOS) vs 'pure' COPD: a distinct phenotype? Allergy 2017; 72:137-145. [PMID: 27501862 DOI: 10.1111/all.13004] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/06/2016] [Indexed: 12/15/2022]
Abstract
BACKGROUND Some studies suggest that asthma-COPD overlap syndrome (ACOS) is associated with worse outcomes than chronic obstructive pulmonary disease (COPD). The goal of this study was to further explore the clinical characteristics and survival of patients with ACOS identified in a real-life cohort of patients with COPD. METHODS Data from the French COPD cohort 'INITIATIVES BronchoPneumopathie Chronique Obstructive' (n = 998 patients) were analyzed to assess the frequency of ACOS defined as a physician diagnosis of asthma before the age of 40 years and to analyze its impact. Univariate analyses were performed to assess the relationship between ACOS and sociodemographic characteristics, risk factors (smoking, occupational exposure, atopic diseases), symptoms (chronic bronchitis, dyspnea-modified Medical Research Council scale and baseline dyspnea index), quality of life (QoL), mood disorders, exacerbations, comorbidities, lung function, prescribed treatment, and survival. RESULTS ACOS was diagnosed in 129 patients (13%). In multivariate analyses, ACOS was associated negatively with cumulative smoking (odds ratio [OR]: 0.992; 95% CI 0.984-1.000 per pack-year) and positively with obesity: OR: 1.97 [1.22-3.16], history of atopic disease (hay fever: OR: 5.50 [3.42-9.00] and atopic dermatitis: OR 3.76 [2.14-6.61]), and drug use (LABA + ICS: 1.86 [1.27-2.74], antileukotrienes 4.83 [1.63-14.34], theophylline: 2.46 [1.23-4.91], and oral corticosteroids: [2.99;.1.26-7.08]). No independent association was found with dyspnea, QoL, exacerbations, and mortality. CONCLUSIONS Compared to 'pure' COPD patients, patients with ACOS exhibit lower cumulative smoking, suffer more from obesity and atopic diseases, and use more asthma treatments. Disease severity (dyspnea, QoL, exacerbations, comorbidities) and prognosis (mortality) are not different from 'pure' COPD patients.
Collapse
Affiliation(s)
- D. Caillaud
- Pulmonary Department; Gabriel Montpied University Hospital; Auvergne University; Clermont-Ferrand France
| | - P. Chanez
- Pulmonary Department; APHM; INSERM U1077; CNRS UMR 7733 Aix Marseille Université; Marseille France
| | - R. Escamilla
- Pulmonary Department; Larrey University Hospital; Toulouse France
| | - P-R. Burgel
- Respiratory and Intensive Care Medicine; Cochin Hospital; AP-HP and Paris Descartes University; Sorbonne Paris Cité; Paris France
| | | | - P. Nesme-Meyer
- Pulmonary Department; La Croix Rousse University Hospital; Lyon France
| | - G. Deslee
- Pulmonary Department; Maison Blanche University Hospital; INSERM U903; Reims France
| | - T. Perez
- Clinique des Maladies Respiratoires; Albert Calmette University Hospital; Lille France
| | | | - C. Pinet
- Polyclinique Les Fleurs; Pneumologie; Ollioules France
| | - G. Jebrak
- Pulmonary Department; Bichat Hospital; AP-HP; Paris France
| | - N. Roche
- Respiratory and Intensive Care Medicine; Cochin Hospital; AP-HP and Paris Descartes University; Sorbonne Paris Cité; Paris France
| | | |
Collapse
|
20
|
Cabon Y, Molinari N, Marin G, Vachier I, Gamez AS, Chanez P, Bourdin A. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy 2016; 47:129-138. [PMID: 27859832 DOI: 10.1111/cea.12853] [Citation(s) in RCA: 84] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Inconsistent results have been reported regarding IL-5 blockade treatment in asthma. There were no direct between-treatment comparisons. Only differences between each drug and placebo were studied. We identified all RCTs with anti-IL5 treatments for patients with asthma over the 1990-September 2015 period. RCTs were searched on Medline, Cochrane and Embase. At least 50 patients were enrolled in each study. Outcomes considered were exacerbation rate reduction, FEV1 changes, ACQ-5 improvement, adverse events and serious adverse events. A global meta-analysis was first conducted followed by an indirect comparison of each IL-5-targeting drug: benralizumab, reslizumab and mepolizumab. Further eosinophilic subgroup analysis and sensitivity analysis were also conducted in case of heterogeneity. Ten trials involving 3421 patients were eligible for meta-analysis. IL-5 blockade significantly reduced annual exacerbation rates vs. placebo by 40% [29-50] (P < 0.01, I2 = 0.61). ACQ-5 was significantly improved vs. placebo but below the recognized MCID level (-0.31 [-0.41, -0.21], P < 0.01, I2 = 0.11). FEV1 changes from baseline were improved vs. placebo by 0.09 L [0.05-0.12] (P < 0.01, I2 = 0.28). The subgroup analysis identified a slight additional improvement in mean treatment effects in eosinophilic (> 300 mm3 /L) patients with severe asthma. Similar patterns and rates of adverse events and severe adverse events were reported with the three drugs. The data interpretations were not affected by the sensitivity analysis. IL-5 blockade appears to be a relevant treatment strategy to improve severe asthma management, particularly for eosinophilic patients. No clear superiority appeared between the drugs when appropriate doses were compared.
Collapse
Affiliation(s)
- Y Cabon
- Department of Medical Information, Montpellier University Hospital, Montpellier, France
| | - N Molinari
- Department of Medical Information, Montpellier University Hospital, Montpellier, France.,PhyMedExp, INSERM U1046, CNRS UMR 9214, University of Montpellier, Montpellier, France
| | - G Marin
- Department of Medical Information, Montpellier University Hospital, Montpellier, France
| | - I Vachier
- Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France
| | - A S Gamez
- Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France
| | - P Chanez
- AP HM Marseille, Marseille, France
| | - A Bourdin
- PhyMedExp, INSERM U1046, CNRS UMR 9214, University of Montpellier, Montpellier, France.,Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France
| |
Collapse
|
21
|
Raherison C, Bourdin A, Bonniaud P, Deslée G, Garcia G, Leroyer C, Taillé C, De Blic J, Dubus JC, Tillié-Leblond I, Chanez P. Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Société de pneumologie de langue française (SPLF) (summary). Rev Mal Respir 2016; 33:271-8. [PMID: 27117926 DOI: 10.1016/j.rmr.2016.03.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Accepted: 02/17/2016] [Indexed: 10/21/2022]
Affiliation(s)
- C Raherison
- Université de Bordeaux, Inserm U1219, ISPED, CHU de Bordeaux, service des maladies respiratoires, pôle cardio-thoracique, 33000 Bordeaux, France.
| | - A Bourdin
- Université Montpellier 1, Inserm U1046, CHU de Montpellier, département de pneumologie et addictologie, hôpital Arnaud-de-Villeneuve, 34000 Montpellier, France
| | - P Bonniaud
- Université de Bourgogne, Inserm U866, CHU de Bourgogne, service de pneumologie et soins intensifs respiratoires, 21079 Dijon, France
| | - G Deslée
- Université de Reims-Champagne-Ardennes, CHU Maison-Blanche, service de pneumologie, 51000 Reims, France
| | - G Garcia
- Université Paris-Sud, Faculté de Médecine, AP-HP, Centre National de Référence de l'Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation, UMRS 999, Inserm, Hôpital de Bicêtre, service de pneumologie, 94270 Le Kremlin-Bicêtre, France
| | - C Leroyer
- Université de Bretagne Occidentale, CHU de la Cavale-Blanche, département de médecine interne et de pneumologie, 29000 Brest, France
| | - C Taillé
- Université Paris-Diderot, AP-HP, hôpital Bichat, service de pneumologie, Centre de compétence des maladies pulmonaires rares, département hospitalo-universitaire FIRE, 75018 Paris, France
| | - J De Blic
- Hôpital Necker-Enfants-Malades, service de pneumologie et allergologie pédiatriques, 75743 Paris, France
| | - J-C Dubus
- Hôpital Nord, unité de pneumologie et médecine infantile, 13000 Marseille, France
| | - I Tillié-Leblond
- CHRU de Lille, service de pneumo-allergologie, 59000 Lille, France
| | - P Chanez
- Université Aix-Marseille, UMR 7333 Inserm U 1067, AP-HM, hôpital Nord, service de pneumologie, 13000 Marseille, France
| |
Collapse
|
22
|
Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg C, Girodet PO, Berger P, Kline JN, Khatri S, Chanez P, Susulic VS, Barnathan ES, Baribaud F, Loza MJ. Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study. Respir Res 2016; 17:43. [PMID: 27107814 PMCID: PMC4842260 DOI: 10.1186/s12931-016-0360-5] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Accepted: 04/15/2016] [Indexed: 12/15/2022] Open
Abstract
Background Asthma is a biologically heterogeneous disease and development of novel therapeutics requires understanding of pathophysiologic phenotypes. There is uncertainty regarding the stability of clinical characteristics and biomarkers in asthma over time. This report presents the longitudinal stability over 12 months of clinical characteristics and clinically accessible biomarkers from ADEPT. Methods Mild, moderate, and severe asthma subjects were assessed at 5 visits over 12 months. Assessments included patient questionnaires, spirometry, bronchodilator reversibility, fractional exhaled nitric oxide (FENO), and biomarkers measured in induced sputum. Results Mild (n = 52), moderate (n = 55), and severe (n = 51) asthma cohorts were enrolled from North America and Western Europe. For all clinical characteristics and biomarkers, group mean data showed no significant change from visit to visit. However, individual data showed considerable variability. FEV1/FVC ratio showed excellent reproducibility while pre-bronchodilator FEV1 and FVC were only moderately reproducible. Of note bronchodilator FEV1 reversibility showed low reproducibility, with the nonreversible phenotype much more reproducible than the reversible phenotype. The 7-item asthma control questionnaire (ACQ7) demonstrated moderate reproducibility for the combined asthma cohorts, but the uncontrolled asthma phenotype (ACQ7 > 1.5) was inconstant in mild and moderate asthma but stable in severe asthma. FENO demonstrated good reproducibility, with the FENO-low phenotype (FENO < 35 ppb) more stable than the FENO-high phenotype (FENO ≥ 35 ppb). Induced sputum inflammatory phenotypes showed marked variability across the 3 sputum samples taken over 6 months. Conclusions The ADEPT cohort showed group stability, individual stability in some parameters e.g. low FEV1/FVC ratio, and low FENO, but marked individual variability in other clinical characteristics and biomarkers e.g. type-2 biomarkers over 12 months. This variability is possibly related to seasonal variations in climate and allergen exposure, medication changes and acute exacerbations. The implications for patient selection strategies based on clinical biomarkers may be considerable.
Collapse
Affiliation(s)
- P E Silkoff
- Janssen Research & Development LLC, Spring House, PA, USA. .,, Present Address: 715 Bryn Mawr Avenue, Penn Valley, PA, 19072, USA.
| | - M Laviolette
- Institut Universitaire de Cardiologie et Pneumologie de Québec (IUCPQ), 2725, Chemin Ste-Foy, Quebec, QC, G1V 4G5, Canada
| | - D Singh
- Centre for Respiratory Medicine and Allergy, the University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester NHS Foundation Trust, Southmoor Road, Manchester, M23 9QZ, UK
| | - J M FitzGerald
- Institute for Heart and Lung Health, The Lung Centre, Gordon and Leslie Diamond Health Care Centre, 7th Floor, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada
| | - S Kelsen
- Department of Thoracic Medicine and Surgery, Temple University School of Medicine, 401N. Broad St., Philadelphia, PA, 19140, USA
| | - V Backer
- Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital, Bispebjerg bakke 23, DK-2400, Copenhagen, NV, Denmark
| | - C Porsbjerg
- Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital, Bispebjerg bakke 23, DK-2400, Copenhagen, NV, Denmark
| | - P O Girodet
- Centre de Recherche Cardio-Thoracique de Bordeaux, University of Bordeaux, U1045, CIC 1401, F-33000, Bordeaux, France
| | - P Berger
- Centre de Recherche Cardio-Thoracique de Bordeaux, University of Bordeaux, U1045, CIC 1401, F-33000, Bordeaux, France
| | - J N Kline
- Division of Pulmonary, Critical Care, and Occupational Medicine, University of Iowa, W219B GH UIHC, 200 Hawkins Drive, Iowa City, IA, 52242, USA
| | - S Khatri
- Department of Pulmonary and Critical Care, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA
| | - P Chanez
- Pneumologie, Aix Marseille University, APHM/INSERM U1067, Chemin des Bourellys 13015, Marseille, France
| | - V S Susulic
- Janssen Research & Development LLC, Spring House, PA, USA
| | - E S Barnathan
- Janssen Research & Development LLC, Spring House, PA, USA
| | - F Baribaud
- Janssen Research & Development LLC, Spring House, PA, USA
| | - M J Loza
- Janssen Research & Development LLC, Spring House, PA, USA
| | | |
Collapse
|
23
|
Raherison C, Bourdin A, Bonniaud P, Deslée G, Garcia G, Leroyer C, Taillé C, De Blic J, Dubus JC, Tillié-Leblond I, Chanez P. Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Société de Pneumologie de Langue Française (SPLF) (Full length text). Rev Mal Respir 2016; 33:279-325. [PMID: 27147308 DOI: 10.1016/j.rmr.2016.03.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- C Raherison
- Inserm U1219, ISPED, service des maladies respiratoires, pôle cardio-thoracique, CHU de Bordeaux, université de Bordeaux, 33000 Bordeaux, France.
| | - A Bourdin
- Inserm U1046, département de pneumologie et addictologie, hôpital Arnaud-de-Villeneuve, CHU de Montpellier, université Montpellier 1, 34000 Montpellier, France
| | - P Bonniaud
- Inserm U866, service de pneumologie et soins intensifs respiratoires, CHU de Bourgogne, université de Bourgogne, 21079 Dijon, France
| | - G Deslée
- Service de pneumologie, CHU Maison-Blanche, université de Reims - Champagne-Ardennes, 51000 Reims, France
| | - G Garcia
- Inserm, UMRS 999, service de pneumologie, département hospitalo-universitaire (DHU) thorax innovation, hôpital de Bicêtre, Centre national de référence de l'hypertension pulmonaire sévère, faculté de médecine, université Paris-Sud, AP-HP, 94270 Le Kremlin-Bicêtre, France
| | - C Leroyer
- Département de médecine interne et de pneumologie, CHU de la Cavale-Blanche, université de Bretagne Occidentale, 29000 Brest, France
| | - C Taillé
- Service de pneumologie, département hospitalo-universitaire FIRE, centre de compétence des maladies pulmonaires rares, hôpital Bichat, université Paris-Diderot, AP-HP, 75018 Paris, France
| | - J De Blic
- Service de pneumologie et allergologie pédiatriques, hôpital Necker-Enfants-Malades, 75743 Paris, France
| | - J-C Dubus
- Unité de pneumologie et médecine infantile, hôpital Nord, 13000 Marseille, France
| | - I Tillié-Leblond
- Service de pneumo-allergologie, CHRU de Lille, 59000 Lille, France
| | - P Chanez
- UMR 7333 Inserm U 1067, service de pneumologie, hôpital Nord, université Aix Marseille, AP-HM, 13000 Marseille, France
| |
Collapse
|
24
|
Perez T, Chanez P, Dusser D, Devillier P. Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea. Allergy 2016; 71:108-14. [PMID: 26466328 DOI: 10.1111/all.12789] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/10/2015] [Indexed: 12/27/2022]
Abstract
BACKGROUND In asthma, inflammation affects both the proximal and distal airways and may induce significant hyperinflation (HI). This study sought to evaluate the prevalence of HI in asthmatic patients with poorly controlled disease and/or dyspnea. METHODS Poor asthma control was defined by an Asthma Control Test (ACT) score <20 (n = 287), and dyspnea was defined as a modified Medical Research Council score ≥1 (n = 18). HI was defined as either a residual volume/total lung capacity (RV/TLC) above the upper limit of normal (RV-HI) or a functional residual capacity (FRC) >120% predicted (FRC-HI). HI reversibility after administration of salbutamol (400 μg) was defined as a decrease in RV >20% or a reduction in FRC >10%. Changes in dyspnea and chest tightness were evaluated on a visual analogue scale. RESULTS Both RV-HI and FRC-HI were observed in 48% of the 305 patients (mean ± SD age: 49 ± 17; FEV1 : 75 ± 18% predicted) included in the study. The prevalence of HI was higher in patients with a FEV1 <60% predicted (93% for RV-HI and 71% for FRC-HI, vs 21% and 41% in patients with a FEV1 > 80%). In patients with HI, the ACT score was lower and chest tightness higher. HI reversibility was obtained in 38% of the asthmatics with FRC-HI and 29% of the asthmatics with RV-HI, whereas FEV1 reversibility was obtained in half of these patients. CONCLUSIONS HI is highly prevalent in poorly controlled asthmatics suggesting small airway dysfunction and may represent an additional criteria for evaluating responsiveness to bronchodilators.
Collapse
Affiliation(s)
- T. Perez
- Service de Pneumologie et des EFR; CHU Lille; et INSERM U1019; Université Lille; Lille France
| | - P. Chanez
- Clinique des Bronches; Allergie et Sommeil; Hôpital Nord; Chemin des Bourrelly; Marseille France
| | - D. Dusser
- Service de Pneumologie; Hôpital Cochin; AP-HP; Université Paris Descartes; Sorbonne Paris Cité; Paris France
| | - P. Devillier
- UPRES EA 220; Université Versailles Saint-Quentin; Hôpital Foch; Suresnes France
| |
Collapse
|
25
|
Charpin D, Pahus L, Sofalvi T, Gras D, Gouitaa M, Chanez P. Absence d’augmentation de la réactivité bronchique à la méthacholine durant la saison pollinique chez les patients allergies au pollen de cyprès. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Arroyo B, Guinde J, Gouitaa M, Tummino C, Charpin D, Chanez P, Palot A. Exacerbation de BPCO secondaire à l’inhalation accidentelle de liquide de cigarette électronique. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Silkoff PE, Strambu I, Laviolette M, Singh D, FitzGerald JM, Lam S, Kelsen S, Eich A, Ludwig-Sengpiel A, Hupp GC, Backer V, Porsbjerg C, Girodet PO, Berger P, Leigh R, Kline JN, Dransfield M, Calhoun W, Hussaini A, Khatri S, Chanez P, Susulic VS, Barnathan ES, Curran M, Das AM, Brodmerkel C, Baribaud F, Loza MJ. Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study. Respir Res 2015; 16:142. [PMID: 26576744 PMCID: PMC4650115 DOI: 10.1186/s12931-015-0299-y] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 10/31/2015] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Asthma is a heterogeneous disease and development of novel therapeutics requires an understanding of pathophysiologic phenotypes. The purpose of the ADEPT study was to correlate clinical features and biomarkers with molecular characteristics, by profiling asthma (NCT01274507). This report presents for the first time the study design, and characteristics of the recruited subjects. METHODS Patients with a range of asthma severity and healthy non-atopic controls were enrolled. The asthmatic subjects were followed for 12 months. Assessments included history, patient questionnaires, spirometry, airway hyper-responsiveness to methacholine, fractional exhaled nitric oxide (FENO), and biomarkers measured in induced sputum, blood, and bronchoscopy samples. All subjects underwent sputum induction and 30 subjects/cohort had bronchoscopy. RESULTS Mild (n = 52), moderate (n = 55), severe (n = 51) asthma cohorts and 30 healthy controls were enrolled from North America and Western Europe. Airflow obstruction, bronchodilator response and airways hyperresponsiveness increased with asthma severity, and severe asthma subjects had reduced forced vital capacity. Asthma control questionnaire-7 (ACQ7) scores worsened with asthma severity. In the asthmatics, mean values for all clinical and biomarker characteristics were stable over 12 months although individual variability was evident. FENO and blood eosinophils did not differ by asthma severity. Induced sputum eosinophils but not neutrophils were lower in mild compared to the moderate and severe asthma cohorts. CONCLUSIONS The ADEPT study successfully enrolled asthmatics across a spectrum of severity and non-atopic controls. Clinical characteristics were related to asthma severity and in general asthma characteristics e.g. lung function, were stable over 12 months. Use of the ADEPT data should prove useful in defining biological phenotypes to facilitate personalized therapeutic approaches.
Collapse
Affiliation(s)
- P E Silkoff
- Janssen Research & Development LLC, 1400 McKean Rd, Springhouse, PA, 19477, USA.
| | - I Strambu
- Arensia Exploratory Medicine, Sos. Viilor 90, Bucharest, 050159, Romania.
| | - M Laviolette
- Institut Universitaire de Cardiologie et Pneumologie de Québec (IUCPQ), 2725, Chemin Ste-Foy, Québec, G1V 4G5, Canada.
| | - D Singh
- Medicines Evaluation Unit, University Hospital of South Manchester Foundation Trust, University of Manchester, Southmoor Road, Manchester, M23 9QZ, UK.
| | - J M FitzGerald
- Institute for Heart and Lung Health, The Lung Centre, 7th Floor, Gordon, Canada. .,Leslie Diamond Health Care Centre, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
| | - S Lam
- Institute for Heart and Lung Health, The Lung Centre, 7th Floor, Gordon, Canada.,Leslie Diamond Health Care Centre, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada
| | - S Kelsen
- Department of Thoracic Medicine and Surgery, Temple University School of Medicine, 3401 N. Broad St., Philadelphia, PA, 19140, USA.
| | - A Eich
- IKF Pneumologie Frankfurt, Institut für klinische Forschung Pneumologie, Clinical Research Centre Respiratory Diseases, Schaumainkai 101-103, Stresemannallee, 360596, Frankfurt, Germany.
| | - A Ludwig-Sengpiel
- KLB Gesundheitsforschung Lübeck GmbH, Sandstr. 18, 23552, Lübeck, Germany.
| | - G C Hupp
- Yale Center for Asthma and Airway Disease, Division of Pulmonary and Critical Care and Sleep Medicine, Yale School of Medicine, TAC 441, 300 Cedar Street, New Haven, CT, 06520, USA.
| | - V Backer
- Department of Respiratory Medicine, Respiratory Research Unit, Bispebjerg University Hospital, Bispebjerg bakke 23, DK-2400, Copenhagen, NV, Denmark.
| | - C Porsbjerg
- Department of Respiratory Medicine, Respiratory Research Unit, Bispebjerg University Hospital, Bispebjerg bakke 23, DK-2400, Copenhagen, NV, Denmark.
| | - P O Girodet
- Univ. Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, INSERM U1045, CIC 1401, F-33000, Bordeaux, France
| | - P Berger
- Univ. Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, INSERM U1045, CIC 1401, F-33000, Bordeaux, France.
| | - R Leigh
- Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada.
| | - J N Kline
- Division of Pulmonary, C ritical Care, and Occupational Medicine, University of Iowa, W219B GH UIHC, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
| | - M Dransfield
- Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham & Birmingham VA Medical Center, 422 THT, 1900 University Blvd, Birmingham, AL, 35294, USA.
| | - W Calhoun
- 4.116 John Sealy Annex, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555-0568, USA.
| | - A Hussaini
- Parexel International, Shelton Simmons (MD), 3001 S Hanover St #7, Brooklyn, MD, 21225, USA.
| | - S Khatri
- Department of Pulmonary and Critical Care, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
| | - P Chanez
- Department of Respiratory Diseases and CIC Nord AP-HM, UMR INSERM U1067 CNRS 7733, Aix-Marseille Université, Marseille, France.
| | - V S Susulic
- Janssen Research & Development LLC, 1400 McKean Rd, Springhouse, PA, 19477, USA
| | - E S Barnathan
- Janssen Research & Development LLC, 1400 McKean Rd, Springhouse, PA, 19477, USA
| | - M Curran
- Janssen Research & Development LLC, 1400 McKean Rd, Springhouse, PA, 19477, USA
| | - A M Das
- Janssen Research & Development LLC, 1400 McKean Rd, Springhouse, PA, 19477, USA
| | - C Brodmerkel
- Janssen Research & Development LLC, 1400 McKean Rd, Springhouse, PA, 19477, USA
| | - F Baribaud
- Janssen Research & Development LLC, 1400 McKean Rd, Springhouse, PA, 19477, USA
| | - M J Loza
- Janssen Research & Development LLC, 1400 McKean Rd, Springhouse, PA, 19477, USA
| |
Collapse
|
28
|
Schuijs MJ, Willart MA, Vergote K, Gras D, Deswarte K, Ege MJ, Madeira FB, Beyaert R, van Loo G, Bracher F, von Mutius E, Chanez P, Lambrecht BN, Hammad H. Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. Science 2015; 349:1106-10. [DOI: 10.1126/science.aac6623] [Citation(s) in RCA: 393] [Impact Index Per Article: 43.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
29
|
Klerlein M, Touri L, Durand C, Mossuz V, Molinari N, Chanez P. Exposition aux nanoparticules en milieu aéroportuaire : étude des condensats d’air exhalé et des fonctions respiratoires selon différents niveaux d’exposition. ARCH MAL PROF ENVIRO 2015. [DOI: 10.1016/j.admp.2015.04.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Khelloufi MK, Garulli C, Viallat A, Chanez P, Gras D. L’organisation spatiale de touffes de cils gouverne le transport de mucus dans les voies aériennes. Application à l’asthme sévère. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.02.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
31
|
Watz H, Calverley P, Chanez P, Dahl R, Decramer M, Disse B, Finnigan H, Kirsten AM, Rodriguez-Roisin R, Tetzlaff K, Towse L, Wouters E, Magnussen H. The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study. Pneumologie 2015. [DOI: 10.1055/s-0035-1544631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
32
|
Magnussen H, Chanez P, Dahl R, Decramer M, Disse B, Finnigan H, Kirsten AM, Rodriguez-Roisin R, Tetzlaff K, Towse L, Watz H, Wouters E, Calverley P. The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study. Pneumologie 2015. [DOI: 10.1055/s-0035-1544632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
33
|
Deslée G, Burgel PR, Escamilla R, Chanez P, Court-Fortune I, Nesme-Meyer P, Brinchault-Rabin G, Paillasseur JL, Perez T, Jebrak G, Caillaud D, Roche N. La toux contribue de façon indépendante à l’altération de la qualité de vie au cours de la BPCO. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
34
|
Tissier-Ducamp D, Martinez S, Alagha K, Charpin D, Chanez P, Palot A. [Bilateral diaphragmatic paralysis due to Parsonage-Turner syndrome]. Rev Mal Respir 2014; 32:742-6. [PMID: 25534571 DOI: 10.1016/j.rmr.2014.11.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2014] [Accepted: 11/11/2014] [Indexed: 11/24/2022]
Abstract
We report the case of a 49-years-old patient who presented to the accident and emergency department with sudden onset dyspnea associated with acute shoulder pain. He was breathless at rest with supine hypoxemia. He had an amyotrophic left shoulder with localized paresis of the shoulder. Both hemi-diaphragms were elevated on chest X-rays. Pulmonary function tests showed a restrictive pattern and both phrenic nerve conduction velocities were decreased. At night, alveolar hypoventilation was evidenced by elevated mean capnography (PtcCO2: 57mmHg). Neuralgic amyotrophy, Parsonage-Turner syndrome was the final diagnosis. This syndrome is a brachial plexus neuritis with a predilection for the suprascapular and axillary nerves. Phrenic nerve involvement is rare but where present can be the most prominent clinical feature as in our case report.
Collapse
Affiliation(s)
- D Tissier-Ducamp
- Clinique des bronches, allergies et du sommeil, Aix Marseille université, AP-HM, 13000 Marseille, France.
| | - S Martinez
- Clinique des bronches, allergies et du sommeil, Aix Marseille université, AP-HM, 13000 Marseille, France
| | - K Alagha
- Clinique des bronches, allergies et du sommeil, Aix Marseille université, AP-HM, 13000 Marseille, France
| | - D Charpin
- Clinique des bronches, allergies et du sommeil, Aix Marseille université, AP-HM, 13000 Marseille, France
| | - P Chanez
- Clinique des bronches, allergies et du sommeil, Aix Marseille université, AP-HM, 13000 Marseille, France
| | - A Palot
- Clinique des bronches, allergies et du sommeil, Aix Marseille université, AP-HM, 13000 Marseille, France
| |
Collapse
|
35
|
Chanez P, Boulet LP, Brillet PY, Joos G, Laviolette M, Louis R, Rochat T, Soccal P, Aubier M. [Bronchial thermoplasty in the treatment of severe adult asthma]. Rev Mal Respir 2014; 32:97-109. [PMID: 25534552 DOI: 10.1016/j.rmr.2014.09.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2014] [Accepted: 09/30/2014] [Indexed: 10/24/2022]
Abstract
Bronchial thermoplasty is a recent endoscopic technique for the treatment of severe asthma. It is an innovative treatment whose clinical efficacy and safety are beginning to be better understood. Since this is a device-based treatment, the evaluation procedure of risks and benefits is different that for pharmaceutical products; safety aspects, regulatory requirements, study design and the assessment of the magnitude of effects may all be different. The mechanism of action and optimal patient selection need to be assessed further in rigorous clinical and scientific studies. This technique is in harmony with the development of personalised medicine in the 21st century. It should be developed further in response to the numerous challenges and needs not yet met in the management of severe asthma.
Collapse
Affiliation(s)
- P Chanez
- Inserm U1067 CNRS UMR 7333, service de pneumologie, AP-HM, Aix Marseille université, chemin des Bourrely, 13015 Marseille, France.
| | - L-P Boulet
- Centre de recherche, institut de cardiologie et de pneumologie de l'université Laval Québec, Québec, Canada
| | - P-Y Brillet
- Département de radiologie, AP-HP Avicenne, 93000 Bobigny, France
| | - G Joos
- Département de pneumologie, CHU de Gand, université de Gand, Gand, Belgique
| | - M Laviolette
- Centre de recherche, institut de cardiologie et de pneumologie de l'université Laval Québec, Québec, Canada
| | - R Louis
- Département de pneumologie, CHU de Liège, GIGAI3 groupe de recherche, université de Liège, Liège, Belgique
| | - T Rochat
- Département de pneumologie, hôpitaux universitaires de Genève, Genève, Suisse
| | - P Soccal
- Département de pneumologie, hôpitaux universitaires de Genève, Genève, Suisse
| | - M Aubier
- U700 Inserm DHU, service de pneumologie, AP-HP Bichat, université Diderot Paris, 75018 Paris, France
| |
Collapse
|
36
|
Dinh-Xuan AT, Annesi-Maesano I, Berger P, Chambellan A, Chanez P, Chinet T, Degano B, Delclaux C, Demange V, Didier A, Garcia G, Magnan A, Mahut B, Roche N. Contribution of exhaled nitric oxide measurement in airway inflammation assessment in asthma. A position paper from the French Speaking Respiratory Society. Rev Mal Respir 2014; 32:193-215. [PMID: 25704902 DOI: 10.1016/j.rmr.2014.11.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Accepted: 08/27/2014] [Indexed: 01/06/2023]
Abstract
Nitric oxide (NO) is both a gas and a ubiquitous inter- and intracellular messenger with numerous physiological functions. As its synthesis is markedly increased during inflammatory processes, NO can be used as a surrogate marker of acute and/or chronic inflammation. It is possible to quantify fractional concentration of NO in exhaled breath (FENO) to detect airway inflammation, and thus improve the diagnosis of asthma by better characterizing asthmatic patients with eosinophilic bronchial inflammation, and eventually improve the management of targeted asthmatic patients. FENO measurement can therefore be viewed as a new, reproducible and easy to perform pulmonary function test. Measuring FENO is the only non-invasive pulmonary function test allowing (1) detecting, (2) quantifying and (3) monitoring changes in inflammatory processes during the course of various respiratory disorders, including corticosensitive asthma.
Collapse
Affiliation(s)
- A T Dinh-Xuan
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Service de physiologie-explorations fonctionnelles, université Paris-Descartes, hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| | - I Annesi-Maesano
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Inserm et université de médecine Pierre-et-Marie-Curie, 75571 Paris cedex 12, France
| | - P Berger
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Centre de recherche cardio-thoracique Inserm U1045, université de Bordeaux, 33076 Bordeaux cedex, France
| | - A Chambellan
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Inserm UMR 1087, institut du thorax, 44007 Nantes cedex, France
| | - P Chanez
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Service de pneumologie, hôpital Nord, chemin des Bourrelly, 13015 Marseille, France
| | - T Chinet
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Service de pneumologie, CHU Ambroise-Paré, 92104 Boulogne, France
| | - B Degano
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Explorations fonctionnelles, hôpital Jean-Minjoz, centre hospitalier régional universitaire, 25000 Besançon, France
| | - C Delclaux
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 75015 Paris, France
| | - V Demange
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Département épidémiologie en entreprise, INRS, rue du Morvan, 54500 Vandoeuvre-lès-Nancy, France
| | - A Didier
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Service de pneumologie, CHU de Toulouse, 24, chemin de Pouvourville - TSA, 31059 Toulouse cedex 9, France
| | - G Garcia
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Service de physiologie, hôpital Bicêtre, Assistance publique-Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre, France
| | - A Magnan
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Inserm UMR 915, institut du thorax, CHU de Nantes, 44007 Nantes cedex, France
| | - B Mahut
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Cabinet de pédiatrie, 4, avenue de la Providence, 92160 Antony, France
| | - N Roche
- Groupe d'experts de la société de pneumologie de langue française sur la mesure du NO expiré dans l'asthme, société de pneumologie de langue française, 66, boulevard Saint-Michel, 75006 Paris, France; Service de pneumologie et soins intensifs respiratoires, Hôtel Dieu, groupe hospitalier Cochin-Broca, 75014 Paris, France
| | | |
Collapse
|
37
|
Kupczyk M, ten Brinke A, Sterk PJ, Bel EH, Papi A, Chanez P, Nizankowska-Mogilnicka E, Gjomarkaj M, Gaga M, Brusselle G, Dahlén B, Dahlén SE. Frequent exacerbators--a distinct phenotype of severe asthma. Clin Exp Allergy 2014; 44:212-21. [PMID: 24447083 DOI: 10.1111/cea.12179] [Citation(s) in RCA: 117] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2013] [Revised: 06/13/2013] [Accepted: 06/27/2013] [Indexed: 11/29/2022]
Abstract
BACKGROUND Exacerbations represent a major source of morbidity and mortality in asthma and are a prominent feature of poorly controlled, difficult-to-treat disease. OBJECTIVE The goal of our study was to provide a detailed characterization of the frequent exacerbator phenotype and to identify risk factors associated with frequent and seasonal exacerbations. METHODS Ninety-three severe asthmatics (SA) and 76 mild-to-moderate patients (MA) were screened and prospectively followed up for 1 year (NCT00555607). Medical history, baseline clinical data and biomarkers were used to assess risk factors for frequent exacerbations. RESULTS During the study, 104 exacerbations were recorded in the SA group and 18 in the MA. Frequent exacerbators were characterized by use of higher doses of inhaled (1700 vs. 800 μg) and oral (6.7 vs. 1.7 mg) glucocorticosteroids, worse asthma control (ACQ score 2.3 vs. 1.4), lower quality of life (SGRQ score 48.5 vs. 33.3), higher sputum eosinophils (25.7% vs. 8.2%) and a more rapid decline in FEV1 /FVC ratio (-0.07 vs. -0.01 ΔFEV1 /FVC, frequent vs. non-frequent, respectively, P < 0.05). Exhaled NO > 45 p.p.b. and a history of smoking were associated with an increased risk of frequent exacerbations (odds ratios: 4.32 and 2.90 respectively). CONCLUSION AND CLINICAL RELEVANCE We were able to distinguish and characterize a subphenotype of asthma subjects--frequent exacerbators--who are significantly more prone to exacerbations. Patients with FeNO > 45 p.p.b. and a history of smoking are at increased risk of frequent exacerbations and require careful monitoring in clinical practice.
Collapse
Affiliation(s)
- M Kupczyk
- Center for Allergy Research, Division of Respiratory Medicine and Allergy, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Kupczyk M, Dahlén B, Sterk PJ, Nizankowska-Mogilnicka E, Papi A, Bel EH, Chanez P, Howarth PH, Holgate ST, Brusselle G, Siafakas NM, Gjomarkaj M, Dahlén SE. Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy 2014; 69:1198-204. [PMID: 25039610 DOI: 10.1111/all.12445] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/06/2014] [Indexed: 12/11/2022]
Abstract
BACKGROUND Although asthma is characterized by variable airways obstruction, most studies of asthma phenotypes are cross-sectional. The stability of phenotypes defined either by biomarkers or by physiological variables was assessed by repeated measures over 1 year in the Pan-European BIOAIR cohort of adult asthmatics. METHODS A total of 169 patients, 93 with severe asthma (SA) and 76 with mild-to-moderate asthma (MA), were examined at six or more visits during 1 year. Asthma phenotype clusters were defined by physiological variables (lung function, reversibility and age of onset of the disease) or by biomarkers (eosinophils and neutrophils in induced sputum). RESULTS After 1 year of follow-up, the allocation to clusters was changed in 23.6% of all asthma patients when defined by physiological phenotypes and, remarkably, in 42.3% of the patients when stratified according to sputum cellularity (P = 0.034). In the SA cohort, 30% and 48.6% of the patients changed allocation according to physiological and biomarker clustering, respectively. Variability of phenotypes was not influenced by change in oral or inhaled corticosteroid dose, nor by the number of exacerbations. Lower stability of single and repeated measure was found for all evaluated biomarkers (eosinophils, neutrophils and FeNO) in contrast to good stability of physiological variables (FEV1 ), quality of life and asthma control. CONCLUSION Phenotypes determined by biomarkers are less stable than those defined by physiological variables, especially in severe asthmatics. The data also imply that definition of asthma phenotypes is improved by repeated measures to account for fluctuations in lung function, biomarkers and asthma control.
Collapse
Affiliation(s)
- M. Kupczyk
- Karolinska Institutet; Stockholm Sweden
- Medical University of Lodz; Lodz Poland
| | - B. Dahlén
- Karolinska Institutet; Stockholm Sweden
| | - P. J. Sterk
- University of Amsterdam; Amsterdam the Netherlands
| | | | - A. Papi
- University of Ferrara; Ferrara Italy
| | - E. H. Bel
- University of Amsterdam; Amsterdam the Netherlands
| | - P. Chanez
- University of Marseille; Marseille France
| | | | | | | | | | - M. Gjomarkaj
- Italian National Research Council; Palermo Italy
| | | | | |
Collapse
|
39
|
Carsin A, Oudyi M, Dubus JC, De Blic J, De Lagausie P, Chanez P, Gras D. Effet in vitro des corticoïdes inhalés sur l’activation viro-induite des cellules épithéliales bronchiques d’enfants asthmatiques. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
40
|
Khelloufi MK, Garulli C, Viallat A, Chanez P, Gras D. Activité mucociliaire dans l’asthme sévère. Approche in vitro. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
Froidure A, Shen C, Gras D, Van Snick J, Chanez P, Pilette C. Myeloid dendritic cells are primed in allergic asthma for thymic stromal lymphopoietin-mediated induction of Th2 and Th9 responses. Allergy 2014; 69:1068-76. [PMID: 24888572 DOI: 10.1111/all.12435] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/23/2014] [Indexed: 12/20/2022]
Abstract
BACKGROUND Type 1 myeloid dendritic cells (mDCs) contribute to inception of allergic asthma (AA) and are regulated by epithelial-derived cytokines. OBJECTIVES To evaluate whether mDCs from AA patients are primed for thymic stromal lymphopoietin (TSLP)-driven responses. METHODS mDCs from 18 AA patients and 15 controls were purified using immunomagnetic sorting. Cells were pulsed with TSLP or Dermatophagoides pteronyssinus (Der p) allergen, before FACS phenotyping and co-culture with allogeneic CD4+ T cells. Bronchial biopsies from 15 AA patients and four controls were immunostained for CD1c and TSLP receptor (TSLPR). RESULTS Allergic asthma patients had a higher proportion of TSLPR+ mDCs, in blood and bronchial mucosa. When compared to mDCs from controls, both TSLP- and Der p-pulsed blood mDCs from AA patients induced increased polarization of CD4+ T cells into Th2 cells (IL-5, IL-13, and GATA3+), while only TSLP-mDCs promoted Th9 cells (IL-9 and PU.1+ /IRF4+). In addition, OX40L was induced upon TSLP stimulation and was required for the induction of Th2, but not Th9, cells. In contrast, development of Th9 cells in this model depended on TGF-β1. CONCLUSIONS Our data indicate overlapping but partially distinct effects of TSLP and Der p allergen pathways, showing that DCs are primed in human asthma for TSLP-driven induction of both Th2 and Th9 cells. This novel TSLP/mDC/Th9 axis operates through a distinct, OX40L-independent pathway. These data further highlight the TSLP pathway as a relevant target in human asthma.
Collapse
Affiliation(s)
- A. Froidure
- Institut de Recherche Expérimentale et Clinique; Université Catholique de Louvain and Walloon Institute for Excellence in Lifesciences and Biotechnology (WELBIO); Brussels Belgium
- Cliniques Universitaires Saint-Luc; service de Pneumologie; Brussels Belgium
| | - C. Shen
- Institut de Recherche Expérimentale et Clinique; Université Catholique de Louvain and Walloon Institute for Excellence in Lifesciences and Biotechnology (WELBIO); Brussels Belgium
| | - D. Gras
- INSERM U 1067; CNRS UMR 7333 Aix Marseille Université; Marseille France
| | - J. Van Snick
- Ludwig Institute for Cancer Research; Brussels Belgium
| | - P. Chanez
- INSERM U 1067; CNRS UMR 7333 Aix Marseille Université; Marseille France
- Département des Maladies Respiratoires; Assistance Publique des Hôpitaux de Marseille; Marseille France
| | - C. Pilette
- Institut de Recherche Expérimentale et Clinique; Université Catholique de Louvain and Walloon Institute for Excellence in Lifesciences and Biotechnology (WELBIO); Brussels Belgium
- Cliniques Universitaires Saint-Luc; service de Pneumologie; Brussels Belgium
| |
Collapse
|
42
|
Gagliardo R, Chanez P, Gjomarkaj M, La Grutta S, Bonanno A, Montalbano AM, Di Sano C, Albano GD, Gras D, Anzalone G, Riccobono L, Profita M. The role of transforming growth factor-β1 in airway inflammation of childhood asthma. Int J Immunopathol Pharmacol 2014; 26:725-38. [PMID: 24067469 DOI: 10.1177/039463201302600316] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
TGF-beta-targeting structural and inflammatory cells has been implicated in the mechanisms leading to the inflammatory and restructuring processes in asthma, suggesting an impact of TGF-beta1 signaling on the development and persistency of this disease. We investigated the potential early involvement of TGF-beta1 activity in the immunological and molecular mechanisms underlying progression of inflammation in childhood asthma. We evaluated the levels of TGF-beta1 in induced sputum supernatants (ISSs) and the expression of small mother cell against decapentaplegic (Smad) 2 and Smad7 proteins in induced sputum cells (ISCs) from children with intermittent asthma (IA), moderate asthma (MA) and control subjects (C). Furthermore, we investigated the regulatory role of TGF-beta1 activity on eosinophil and neutrophil adhesion to epithelial cells using adhesion assay, and on the granulocyte expression of adhesion molecule CD11b/CD18 Macrophage-1 antigen (MAC-1), by flow cytometry. We found that the levels of TGF-beta1 are increased in ISSs of IA and MA in comparison to C, concomitantly to the activation of intracellular signaling TGFbeta/Smads pathway in ISCs. In MA, TGF-beta1 levels correlated with the number of sputum eosinophils and neutrophils. Furthermore, we showed the ability of sputum TGF-beta1 to promote eosinophil and neutrophil adhesion to epithelial cells, and to increase the expression of MAC-1 on the granulocyte surface. This study shows the activation of TGFbeta/Smad signaling pathway in the airways of children with IA and, despite the regular ICS treatment, in children with MA, and provides evidence for the contribution of TGF-beta1 in the regulation of granulocyte activation and trafficking.
Collapse
Affiliation(s)
- R Gagliardo
- Institute of Biomedicine and Molecular Immunology, Unit of Immunopathology and Pharmacology of the Respiratory System, A. Maurizio Vignola Laboratories, Italian National Research Council, Palermo, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Caillaud D, Chanez P, Escamilla R, Burgel P, Court-Fortune I, Nesme-Meyer P, Deslee G, Perez T, Pinet C, Roche N. La rhinite chronique (RC) est associée à la dyspnée et à une diminution de la qualité de vie (QdV) dans la BPCO. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
44
|
Khelloufi MK, Gras D, Garulli C, Viallat A, Chanez P. Étude de l’activité mucociliaire dans l’asthme sévère. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
45
|
Burgel P, Deslée G, Jebrak G, Brinchault G, Caillaud D, Chanez P, Court-Fortune I, Escamilla R, Nesme-Meyer P, Paillasseur J, Perez T, Roche N. Corticoïdes inhalés chez les patients atteints de BPCO : comparaison des données de la cohorte INITIATIVES BPCO avec les recommandations GOLD 2007 et 2011. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
46
|
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2013; 43:343-73. [DOI: 10.1183/09031936.00202013] [Citation(s) in RCA: 2274] [Impact Index Per Article: 206.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
47
|
Neino Mourtala Mohamed A, Tummino C, Gouitaa M, Chanez P. [Thrombocytopenia induced by rifampicin not previously sensitized: a case presentation]. Rev Mal Respir 2013; 30:785-8. [PMID: 24267770 DOI: 10.1016/j.rmr.2013.03.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2012] [Accepted: 03/04/2013] [Indexed: 11/29/2022]
Abstract
Thrombocytopenia induced by rifampicin in the absence of prior sensitization is exceptional, especially when it occurs in a patient without risk factors. We report the case of a patient aged 25 years with no past history of medical, surgical or knowledge of having taken rifampicin previously, who was hospitalized for treatment of thrombocytopenic purpura occurring after the initiation of fixed combination quadruple therapy (isoniazid, rifampicin, pyrazinamide and ethambutol) for pulmonary tuberculosis. The biological pretreatment and therapeutic education had not been made. The patient presented with thrombocytopenic purpura 30000/mm(3) on day 9 after the initiation of treatment. The platelet count returned to normal 10 days after discontinuation of treatment. We elected not to reintroduce rifampicin given the strong likelihood that it was responsible for this complication. We conducted a phased reintroduction of isoniazid, ethambutol and pyrazinamide. No recurrence of the thrombocytopenia occurred. Thus, the diagnosis of rifampicin-induced thrombocytopenia appears to have been confirmed and the patient tolerated the remainder of their treatment well.
Collapse
|
48
|
Touri L, Marchetti H, Sari-Minodier I, Molinari N, Chanez P. The airport atmospheric environment: respiratory health at work. Eur Respir Rev 2013; 22:124-30. [DOI: 10.1183/09059180.00005712] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
49
|
Charriot J, Gamez AS, Humbert M, Chanez P, Bourdin A. [Targeted therapies in severe asthma: the discovery of new molecules]. Rev Mal Respir 2013; 30:613-26. [PMID: 24182649 DOI: 10.1016/j.rmr.2013.02.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2012] [Accepted: 02/24/2013] [Indexed: 11/25/2022]
Abstract
The pathophysiological mechanisms involved in the chronicity and phenotypic heterogeneity of asthma offer the prospect of new therapeutic opportunities. A better clinical and biological characterisation of selected patients has led to the development of targeted therapies. Studies are under way to demonstrate their efficacy and tolerance and also their impact on the natural history of the disease. This revue aims to examine the therapies, developed during the last ten years, that are based on the immunological mechanisms involved in the pathophysiology of asthma, essentially in its severe form. The rapid expansion of human monoclonal antibodies has allowed testing of various immunological pathways. Anti-IgE, anti- IL-5, and anti-IL-13 strategies seem the most promising. Antagonists to TNF-alpha and I'IL-4 have not succeeded in reducing the events related to severe asthma in a convincing manner. Molecules targeted against thymic stromal lymphopoietin (TSLP) and I'IL-9 are under development. These approaches are involved in the development of therapeutic programmes adapted to the patient's phenotype, that is to say a personalised approach to care.
Collapse
Affiliation(s)
- J Charriot
- Département des maladies respiratoires, hôpital Arnaud-de-Villeneuve, CHU de Montpellier, 371, avenue du Doyen-Giraud, 34295 Montpellier cedex 5, France
| | | | | | | | | |
Collapse
|
50
|
Bourdin A, Mifsud NA, Chanez B, Chanez P, Snell G, Kotsimbos TC. Clara cells and injury post lung transplantation: an evolving story. Am J Transplant 2013; 13:1370. [PMID: 23465090 DOI: 10.1111/ajt.12184] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|